Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement

Long Liang,1 Mian Mao,2 Lei Wu,1 Taiyu Chen,3 Jiahua Lyu,1 Qifeng Wang,1 Tao Li1 1Department of Radiation Oncology, Sichuan Cancer Hospital and Institution, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Radiation Oncology Key Laboratory of Sichu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liang L, Mao M, Wu L, Chen T, Lyu J, Wang Q, Li T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	lung squamous cell carcinoma eml4-alk rearrangement alectinib lorlatinib sbrt Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/006aed73d451483f92fb8e0c6678d68a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:006aed73d451483f92fb8e0c6678d68a
record_format	dspace
spelling	oai:doaj.org-article:006aed73d451483f92fb8e0c6678d68a2021-12-02T19:17:36ZEfficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement1178-6930https://doaj.org/article/006aed73d451483f92fb8e0c6678d68a2021-12-01T00:00:00Zhttps://www.dovepress.com/efficacy-and-drug-resistance-analysis-of-alk-inhibitors-in-combination-peer-reviewed-fulltext-article-OTThttps://doaj.org/toc/1178-6930Long Liang,1 Mian Mao,2 Lei Wu,1 Taiyu Chen,3 Jiahua Lyu,1 Qifeng Wang,1 Tao Li1 1Department of Radiation Oncology, Sichuan Cancer Hospital and Institution, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Radiation Oncology Key Laboratory of Sichuan Province, Chengdu, People’s Republic of China; 2Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Centre, School of Medicine, University of Electronic Science and Technology of China, Chengdu, People’s Republic of China; 3Clinical Medical College of Chengdu Medical College, Chengdu, 610500, People’s Republic of ChinaCorrespondence: Tao LiDepartment of Radiation Oncology, Sichuan Cancer Hospital Institution, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55, 4th Section of Renmin South Road, Chengdu, People’s Republic of ChinaEmail litaoxmf@126.comAbstract: EML4-ALK rearrangement is common in lung adenocarcinoma. The ALK inhibitors remarkably inhibit lung adenocarcinoma and reveal long-term beneficial effects in several patients. Advanced genetic testing technology reveals that EML4-ALK rearrangement has been observed in patients with lung squamous cell carcinoma. In the present study, we report a case of a 53-year-old patient with EML4-ALK rearranged in lung squamous carcinoma; PET/CT scan revealed brain and multiple bone metastases. First-line ALK-TKI combined with local stereotactic body radiation therapy indicated progression-free survival of 9 months. After progressive disease, treatment was switched to lorlatinib, with little efficacy and a total overall survival of 11 months. The emergence of drug resistance revealed that the genetic test result was EML4-ALK fusion (V3a/b variants), indicating a poor prognosis. In this study, we analyzed the treatment efficacy of ALK inhibitors and provided a research basis for the treatment of EML4-ALK rearranged in lung squamous cell carcinoma patients.Keywords: lung squamous cell carcinoma, EML4-ALK rearrangement, alectinib, lorlatinib, SBRTLiang LMao MWu LChen TLyu JWang QLi TDove Medical Pressarticlelung squamous cell carcinomaeml4-alk rearrangementalectiniblorlatinibsbrtNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENOncoTargets and Therapy, Vol Volume 14, Pp 5385-5389 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	lung squamous cell carcinoma eml4-alk rearrangement alectinib lorlatinib sbrt Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	lung squamous cell carcinoma eml4-alk rearrangement alectinib lorlatinib sbrt Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Liang L Mao M Wu L Chen T Lyu J Wang Q Li T Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement
description	Long Liang,1 Mian Mao,2 Lei Wu,1 Taiyu Chen,3 Jiahua Lyu,1 Qifeng Wang,1 Tao Li1 1Department of Radiation Oncology, Sichuan Cancer Hospital and Institution, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Radiation Oncology Key Laboratory of Sichuan Province, Chengdu, People’s Republic of China; 2Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Centre, School of Medicine, University of Electronic Science and Technology of China, Chengdu, People’s Republic of China; 3Clinical Medical College of Chengdu Medical College, Chengdu, 610500, People’s Republic of ChinaCorrespondence: Tao LiDepartment of Radiation Oncology, Sichuan Cancer Hospital Institution, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55, 4th Section of Renmin South Road, Chengdu, People’s Republic of ChinaEmail litaoxmf@126.comAbstract: EML4-ALK rearrangement is common in lung adenocarcinoma. The ALK inhibitors remarkably inhibit lung adenocarcinoma and reveal long-term beneficial effects in several patients. Advanced genetic testing technology reveals that EML4-ALK rearrangement has been observed in patients with lung squamous cell carcinoma. In the present study, we report a case of a 53-year-old patient with EML4-ALK rearranged in lung squamous carcinoma; PET/CT scan revealed brain and multiple bone metastases. First-line ALK-TKI combined with local stereotactic body radiation therapy indicated progression-free survival of 9 months. After progressive disease, treatment was switched to lorlatinib, with little efficacy and a total overall survival of 11 months. The emergence of drug resistance revealed that the genetic test result was EML4-ALK fusion (V3a/b variants), indicating a poor prognosis. In this study, we analyzed the treatment efficacy of ALK inhibitors and provided a research basis for the treatment of EML4-ALK rearranged in lung squamous cell carcinoma patients.Keywords: lung squamous cell carcinoma, EML4-ALK rearrangement, alectinib, lorlatinib, SBRT
format	article
author	Liang L Mao M Wu L Chen T Lyu J Wang Q Li T
author_facet	Liang L Mao M Wu L Chen T Lyu J Wang Q Li T
author_sort	Liang L
title	Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement
title_short	Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement
title_full	Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement
title_fullStr	Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement
title_full_unstemmed	Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement
title_sort	efficacy and drug resistance analysis of alk inhibitors in combination with stereotactic body radiation therapy for treating lung squamous carcinoma patient harboring eml4-alk rearrangement
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/006aed73d451483f92fb8e0c6678d68a
work_keys_str_mv	AT liangl efficacyanddrugresistanceanalysisofalkinhibitorsincombinationwithstereotacticbodyradiationtherapyfortreatinglungsquamouscarcinomapatientharboringeml4alkrearrangement AT maom efficacyanddrugresistanceanalysisofalkinhibitorsincombinationwithstereotacticbodyradiationtherapyfortreatinglungsquamouscarcinomapatientharboringeml4alkrearrangement AT wul efficacyanddrugresistanceanalysisofalkinhibitorsincombinationwithstereotacticbodyradiationtherapyfortreatinglungsquamouscarcinomapatientharboringeml4alkrearrangement AT chent efficacyanddrugresistanceanalysisofalkinhibitorsincombinationwithstereotacticbodyradiationtherapyfortreatinglungsquamouscarcinomapatientharboringeml4alkrearrangement AT lyuj efficacyanddrugresistanceanalysisofalkinhibitorsincombinationwithstereotacticbodyradiationtherapyfortreatinglungsquamouscarcinomapatientharboringeml4alkrearrangement AT wangq efficacyanddrugresistanceanalysisofalkinhibitorsincombinationwithstereotacticbodyradiationtherapyfortreatinglungsquamouscarcinomapatientharboringeml4alkrearrangement AT lit efficacyanddrugresistanceanalysisofalkinhibitorsincombinationwithstereotacticbodyradiationtherapyfortreatinglungsquamouscarcinomapatientharboringeml4alkrearrangement
_version_	1718376893163503616

Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement

Ejemplares similares